MS, RN, ACNP-BC, AOCN
Nurse Practitioner, Associate Clinical Professor, University of California San Francisco
Improving Diagnosis and Outcomes in Multiple Myeloma: Early Detection and Healthcare Disparities
Multiple myeloma (MM) is a hematologic malignancy that impacts plasma cells in the bone marrow, causing symptoms such as bone lesions, renal injury, anemia, and hypercalcemia....
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Comprehensive Advances in Multiple Myeloma: From Diagnosis to Emerging Therapies
Multiple myeloma is a plasma cell cancer that often develops from precursor conditions like monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (SMM)....
Advances in MRD Testing for Multiple Myeloma: Impact on Prognosis and Treatment Decisions
This article reviews the role of minimal residual disease (MRD) testing in multiple myeloma (MM), highlighting its association with improved progression-free survival and overall survival. MRD-negative status correlates with better...
IsaPd Shows Promise in Dara-R Multiple Myeloma, but Modest PFS Highlights Need for New Therapies
Researchers of a multicenter real-world analysis assessed the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The study...
Impact of Removing 24-Hour Urine Assessments from IMWG Criteria in Patients With MM Post-ASCT
Researchers of this study analyzed the impact of removing 24-hour urine (24HRU) assessments from International Myeloma Working Group (IMWG) response criteria for patients with multiple myeloma (MM) following autologous stem...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Dexamethasone Dose Reductions in NDMM: No Impact on Survival Outcomes
Dexamethasone is a key component of induction therapy for newly diagnosed multiple myeloma (NDMM), but its use is often associated with toxicities such as hyperglycemia and insomnia....
